| P50 | author | Misty M Attwood | Q98892111 |
| | Helgi B Schiöth | Q98892113 |
| | Mathias Rask-Andersen | Q57305482 |
| P2093 | author name string | Jörgen Jonsson | |
| P2860 | cites work | A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors | Q91528336 |
| | Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided? | Q91629062 |
| | Eptinezumab: First Approval | Q91717165 |
| | Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions | Q91737551 |
| | The current state and future directions of RNAi-based therapeutics | Q92209450 |
| | Updates on Aptamer Research | Q92219708 |
| | VEGF in Signaling and Disease: Beyond Discovery and Development | Q92229613 |
| | FDA new drug approvals in Q2 2019 | Q92322903 |
| | Development of therapeutic antibodies for the treatment of diseases | Q92364949 |
| | Considerations for the Design of Antibody-Based Therapeutics | Q92585782 |
| | Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives | Q92586733 |
| | Bispecific antibodies: a mechanistic review of the pipeline | Q92596473 |
| | Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders | Q92710463 |
| | Certolizumab pegol for induction of remission in Crohn's disease | Q93054455 |
| | HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration | Q93100083 |
| | Evaluation of intranasal delivery route of drug administration for brain targeting | Q93200328 |
| | Entering the Modern Era of Gene Therapy | Q93377068 |
| | Immunology of COVID-19: Current State of the Science | Q96156437 |
| | Assessing the Immunogenicity of Biopharmaceuticals | Q26751485 |
| | From selection hits to clinical leads: progress in aptamer discovery | Q26752799 |
| | Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development | Q26775040 |
| | Anti-TNF therapy: past, present and future | Q26997311 |
| | Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial | Q28202166 |
| | Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria | Q28256613 |
| | VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond | Q28260984 |
| | How many drug targets are there? | Q28276660 |
| | The druggable genome | Q29547361 |
| | FDA Approval: Blinatumomab | Q33425875 |
| | The VEGF family in cancer and antibody-based strategies for their inhibition | Q33733437 |
| | Trends in the exploitation of novel drug targets | Q34205159 |
| | Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. | Q34288205 |
| | Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications | Q34415658 |
| | Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy | Q34456790 |
| | Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease | Q34499843 |
| | IL-17 in Chronic Inflammation: From Discovery to Targeting | Q34512003 |
| | Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration | Q34650239 |
| | Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis | Q35291439 |
| | One target, different effects: a comparison of distinct therapeutic antibodies against the same targets | Q35569418 |
| | Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases | Q36164238 |
| | Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis | Q36333938 |
| | Membrane-bound and soluble Fas ligands have opposite functions in photoreceptor cell death following separation from the retinal pigment epithelium. | Q36349972 |
| | Tumor necrosis factor antagonist mechanisms of action: a comprehensive review | Q37043901 |
| | Evidence that cytokines play a role in rheumatoid arthritis | Q37316594 |
| | Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma | Q37426827 |
| | Therapeutic antibodies: successes, limitations and hopes for the future | Q37491236 |
| | A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis | Q37691163 |
| | Engineering the variable region of therapeutic IgG antibodies. | Q37853324 |
| | The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication | Q38135497 |
| | Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer | Q38164658 |
| | Monoclonal antibodies: technologies for early discovery and engineering | Q38633596 |
| | Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases | Q38710802 |
| | Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation. | Q38728589 |
| | Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease | Q38741563 |
| | Immunoglobulin isotype knowledge and application to Fc engineering | Q38785013 |
| | Harnessing Fc receptor biology in the design of therapeutic antibodies | Q38796274 |
| | Pharmacology of Antisense Drugs | Q38978959 |
| | A comprehensive map of molecular drug targets. | Q39026969 |
| | Aptamers as Therapeutics | Q39070782 |
| | MicroRNA therapeutics: towards a new era for the management of cancer and other diseases | Q39139786 |
| | In vitro-engineered non-antibody protein therapeutics | Q39167522 |
| | Affibody molecules as engineered protein drugs | Q39197528 |
| | Targeting ligand-receptor interactions for development of cancer therapeutics | Q39216874 |
| | Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC. | Q39449196 |
| | Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes | Q40513214 |
| | Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists | Q40561067 |
| | Regulated expression and inhibitory function of Fcgamma RIIb in human monocytic cells | Q40763824 |
| | Are Anti-inflammatory Therapies Viable Treatments for Psychiatric Disorders?: Where the Rubber Meets the Road | Q41238621 |
| | Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions | Q41355139 |
| | Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine | Q41696168 |
| | Rilonacept and canakinumab | Q41769940 |
| | Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments | Q41837643 |
| | Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human | Q41874340 |
| | Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug | Q42322578 |
| | The making of bispecific antibodies | Q42323236 |
| | Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis | Q42456197 |
| | The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α. | Q45012824 |
| | Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. | Q45207573 |
| | Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. | Q45987643 |
| | A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors | Q46483294 |
| | Next generation antibody drugs: pursuit of the 'high-hanging fruit'. | Q46527001 |
| | Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy | Q46936282 |
| | A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate | Q46938701 |
| | BAFF- and APRIL-targeted therapy in systemic autoimmune diseases | Q47095865 |
| | Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics. | Q47099672 |
| | DrugBank 5.0: a major update to the DrugBank database for 2018. | Q47128239 |
| | The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. | Q47139831 |
| | The renaissance of complement therapeutics. | Q47336749 |
| | A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression | Q48063321 |
| | Progress in biopharmaceutical development. | Q48253463 |
| | Aptamer Therapeutics in Cancer: Current and Future. | Q52347485 |
| | Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease. | Q52643911 |
| | Unexplored therapeutic opportunities in the human genome. | Q52689109 |
| | Lymphotoxin α stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. | Q54630288 |
| | Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. | Q55025616 |
| | Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942 | Q57163374 |
| | Recent Advances in Therapeutic Vaccines to Treat Hypertension | Q57787203 |
| | Galcanezumab: First Global Approval | Q58094608 |
| | Fremanezumab: First Global Approval | Q58579025 |
| | Revolution in Gene Medicine Therapy and Genome Surgery | Q59349746 |
| | Antibody Approaches To Treat Brain Diseases | Q59589007 |
| | Turning the corner on therapeutic cancer vaccines | Q61797559 |
| | Orphan Drugs and Their Impact on Pharmaceutical Development | Q64045406 |
| | Gene Therapy Leaves a Vicious Cycle | Q64093774 |
| | Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach | Q83016502 |
| | Advances in the assessment and control of the effector functions of therapeutic antibodies | Q83335115 |
| | Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China | Q83767469 |
| | Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope | Q84560524 |
| | Targeting the IL-17-T(H)17 pathway | Q86428633 |
| | The CGRP Pathway in Migraine as a Viable Target for Therapies | Q88479862 |
| | Brolucizumab: is extended VEGF suppression on the horizon? | Q90134775 |
| | David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments | Q90211949 |
| | Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration | Q90355187 |
| | Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review | Q90406658 |
| | Top companies and drugs by sales in 2019 | Q90590525 |
| | Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis | Q91288455 |
| | Role of CGRP in Migraine | Q91374428 |
| P577 | publication date | 2020-09-02 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Soluble ligands as drug targets | |